Publications by authors named "D Aleman-Gonzalez-Duhart"
The prevalence of diabetes is rapidly increasing. The current number of diagnosed cases is 422 million, expected to reach 640 million by 2040. Type 2 diabetes, which constitutes 95% of the cases, is characterized by insulin resistance and a progressive loss of β-cell function.
View Article and Find Full Text PDFArticle Synopsis
- Thiazolidinediones (TZDs) are used for type 2 diabetes treatment but have side effects like weight gain and heart failure.
- The study tested two TZD derivatives (C40 and C81) and a new compound (C4) for their effectiveness in managing diabetes and antioxidant activity in diabetic rats.
- C40 effectively achieved normal blood sugar levels, C81 reduced blood glucose, and C4 showed the best antioxidant benefits without lowering glucose.
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by impaired glucose homeostasis, insulin resistance and hyperglycemia. Among its serious multisystemic complications is diabetic retinopathy (DR), which develops slowly and often insidiously. This disorder-the most common cause of vision loss in working-age adults-is characterized by functional and morphological changes in the retina.
View Article and Find Full Text PDFArticle Synopsis
- Diabetes mellitus (DM) causes complications in microvascular, macrovascular, and nervous systems, but the link to weak bones is less understood.
- Various molecular mechanisms resulting from chronic high blood sugar levels (hyperglycemia) differ depending on the organ and tissue affected.
- The complexity of diabetes treatment stems from individual patient conditions and the side effects of therapies, with an emphasis on the role of osmotic changes, oxidative stress, and inflammation in disease progression.
Diabetes mellitus is a chronic disease characterized by hyperglycemia, insulin resistance and hyperlipidemia. Glitazones or thiazolidinediones (TZD) are drugs that act as insulin-sensitizing agents whose molecular target is the peroxisome proliferator-activated receptor gamma (PPARγ). The euglycemic action of TZD has been linked with the induction of type 4 glucose transporter.
View Article and Find Full Text PDF